Control of CNS Cell-Fate Decisions by SHP-2 and Its Dysregulation in Noonan Syndrome  by Gauthier, Andrée S. et al.
Neuron
ArticleControl of CNS Cell-Fate Decisions
by SHP-2 and Its Dysregulation
in Noonan Syndrome
Andre´e S. Gauthier,1,2,3 Olivia Furstoss,1,2 Toshiyuki Araki,5 Richard Chan,5 Benjamin G. Neel,5
David R. Kaplan,2,3 and Freda D. Miller1,3,4,*
1Developmental Biology Program
2Cell Biology Program
Hospital for Sick Children, 555 University Avenue, Toronto, ON M5G 1X8, Canada
3Department of Molecular and Medical Genetics
4Department of Physiology
University of Toronto, Medical Sciences Building, 1 Kings College Circle, Toronto, ON M5S 1A8, Canada
5Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA
*Correspondence: fredam@sickkids.ca
DOI 10.1016/j.neuron.2007.03.027SUMMARY
Within the developing mammalian CNS, growth
factors direct multipotent precursors to gener-
ate neurons versus glia, a process that if per-
turbed might lead to neural dysfunction. In this
regard, genetic mutations resulting in constitu-
tive activation of the protein tyrosine phospha-
tase SHP-2 cause Noonan Syndrome (NS),
which is associated with learning disabilities
and mental retardation. Here, we demonstrate
that genetic knockdown of SHP-2 in cultured
cortical precursors or in the embryonic cortex
inhibited basal neurogenesis and caused en-
hanced and precocious astrocyte formation.
Conversely, expression of an NS SHP-2 mutant
promoted neurogenesis and inhibited astro-
genesis. Neural cell-fate decisions were simi-
larly perturbed in a mouse knockin model that
phenocopies human NS. Thus, SHP-2 instructs
precursors to make neurons and not astrocytes
during the neurogenic period, and perturba-
tions in the relative ratios of these two cell
types upon constitutive SHP-2 activation may
contribute to the cognitive impairments in NS
patients.
INTRODUCTION
Development of the cerebral cortex involves a common
pool of precursor cells that sequentially generate neurons
and glia. Emerging evidence indicates that both intrinsic
mechanisms and environmental growth factors are impor-
tant for cortical cell-fate decisions (Pearson and Doe,
2004; Guillemot et al., 2006). In particular, appropriateearly neurogenesis requires receptor tyrosine kinase
(RTK)-mediated activation of an MEK-ERK-C/EBP path-
way (Me´nard et al., 2002; Paquin et al., 2005), whereas
the later onset of astrocyte formation requires activation
of the gp130-JAK-STAT pathway (Bonni et al., 1997;
Johe et al., 1996) by neuron-derived cardiotrophin-1
(Barnabe´-Heider et al., 2005).
Implicit in any model where growth factors define neural
cell fate is the assumption that multipotent precursors can
respond to neurogenic and gliogenic factors even at times
when those cell types are not normally generated. Support
for this assumption comes from work showing that cortical
precursors will inappropriately generate astrocytes during
the neurogenic period if prematurely exposed to CNTF
in vivo (Barnabe´-Heider et al., 2005). One way to ensure that
such inappropriate early gliogenesis does not occur is via
intrinsic epigenetic mechanisms that make early cortical
precursors relatively unresponsive to gliogenic cytokines
(reviewed in Pearson and Doe [2004] and Guillemot et al.
[2006]). Here, we have asked whether growth factor sig-
naling provides another way to silence gliogenesis during
the neurogenic period and have focused on the protein
tyrosine phosphatase SHP-2.
SHP-2 is a growth factor-regulated phosphatase that is
widely expressed and modulates both the MEK-ERK and
the gp130-JAK-STAT pathways (Neel et al., 2003; Ernst
and Jenkins, 2004). SHP-2 is recruited to many RTKs
upon activation and is essential for sustained MEK-ERK
activation (Neel et al., 2003). SHP-2 is also recruited to
the activated gp130 receptor and negatively regulates
the gp130-JAK-STAT pathway in some cells (Lehmann
et al., 2003; Ernst and Jenkins, 2004). Thus, SHP-2 is an
ideal candidate for promoting neurogenesis and inhibiting
gliogenesis. Further support for the idea that SHP-2 may
regulate neural development comes from the human
genetic disorder NS, which occurs in 1 in 2500 live births.
NS children present with cardiac defects, craniofacial
abnormalities, and short stature (Noonan, 1994), and aNeuron 54, 245–262, April 19, 2007 ª2007 Elsevier Inc. 245
Neuron
SHP-2 in Neural Precursor CellsFigure 1. SHP-2 Expression Is High in Cortical Precursors during the Neurogenic, but not Gliogenic, Period
(A) Western blot for SHP-2 in equal amounts of lysate from precursors cultured for 1–5 DIV.
(B) Immunocytochemistry for SHP-2 (red) and nestin (top panel, green) or bIII-tubulin (bottom panel, green) in precursors cultured for 2 DIV. Arrows
denote double-labeled cells. Space bar, 50 mm.
(C) Immunocytochemistry for SHP-2 (all panels, red) and nestin (left panels, green) or bIII-tubulin (right top panel, green) in coronal cortical sections at
E12, E15, E17, and P5. Arrows denote nestin-positive, SHP-2-positive precursors in the VZ/SVZ. The broken line demarcates the VZ/SVZ from the
cortical mantle (CM). V, ventricle. Space bar, 50 mm.
(D) Western blot for SHP-2 in lysates from NIH 3T3 cells transfected with SHP-2 shRNA1 or a scrambled shRNA control (scr) for 48 or 72 hr. Blots were
reprobed for ERK to ensure equal protein loading.
(E) Immunocytochemistry for SHP-2 (red) in transfected precursors (green) indicating no or low (no-low), basal or high levels of SHP-2 expression.
Arrows indicate the same transfected cell in the upper and lower panels. Space bar, 25 mm.
(F) Quantification of SHP-2 immunoreactivity as shown in (E) for precursors cotransfected with plasmids encoding EGFP and shRNA1, scrambled
shRNA (scr), or, as a positive control, D61G SHP-2 for 2 DIV.246 Neuron 54, 245–262, April 19, 2007 ª2007 Elsevier Inc.
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SHP-2 in Neural Precursor CellsFigure 2. Genetic Knockdown of SHP-2 Has No Effect on Cortical Precursor Cell Survival or Proliferation but Specifically Inhibits
Neurogenesis
(A) Immunocytochemistry for EGFP (GFP; green) and bIII-tubulin (red) in precursors cotransfected with EGFP and SHP-2 shRNA1 or scrambled
shRNA and cultured 3 DIV. Cells were counterstained with Hoechst 33258. Arrows denote double-labeled, transfected cells, and the arrowhead
denotes an EGFP-positive cell that is not double labeled. Space bar, 50 mm.
(B) Quantification of transfected, bIII-tubulin-positive neurons in experiments similar to (A). Three experiments of eight are shown. In experiment three
(Exp 3), cultures were also cotransfected with murine SHP-2 shRNA1 and HA-tagged human SHP-2 (hWT SHP-2). *p < 0.05, **p < 0.01, ANOVA.
(C–E) Quantification of precursors transfected as in (A), cultured for 2 DIV, and stained for (C) Ki67, (D) caspase-3, or (E) with Hoechst 33258 to monitor
nuclear morphology. In all cases, two experiments of three are shown. p > 0.05, ANOVA (C and D).
(F) Quantification of precursors transfected as in (A), cultured for 3 DIV in the presence of ZVAD and immunostained for bIII tubulin. Results represent
two pooled experiments. ***p < 0.005.
Error bars denote SEM in all cases.large percentage (1/3–1/2) exhibit learning disabilities and
mental retardation (Noonan, 1994; Yoshida et al., 2004;
Lee et al., 2005). Approximately 50% of NS cases are
caused by missense mutations in the human ptpn11
(shp-2) gene (Tartaglia et al., 2001) and result in expres-
sion of a SHP-2 protein with increased basal or stimulated
phosphatase activity (Fragale et al., 2004; Keilhack et al.,
2005). NS has been modeled in the mouse by knocking in
an NS shp-2 allele (Araki et al., 2004), but it is not yetknown whether this mouse model displays neural and/or
cognitive perturbations.
Here, we provide evidence that SHP-2 is essential for
normal cortical cell-fate decisions and that aberrant
activation of SHP-2 in an NS mouse model decreases
astrogenesis and enhances neurogenesis, suggesting
that some cognitive impairments seen in this syndrome
may be due to aberrant neural cell-fate decisions during
development.Neuron 54, 245–262, April 19, 2007 ª2007 Elsevier Inc. 247
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SHP-2 in Neural Precursor CellsFigure 3. SHP-2 Promotes Genesis of Neurons at the Expense of Astrocytes
(A–E) Genetic knockdown of SHP-2 enhances cytokine-mediated gliogenesis. (A) Immunocytochemistry for EGFP (GFP; green) and GFAP (red) in
precursors cotransfected with EGFP and SHP-2 shRNA1, exposed to 50 ng/ml CNTF at 2 DIV, and cultured for 4 more days. Cells were counter-
stained with Hoechst 33258. Arrows denote double-labeled, transfected cells. Space bar, 50 mm. (B and C) Quantification of transfected cells
expressing (B) GFAP or (C) CD44 in experiments similar to (A). *p < 0.05, ***p < 0.005, ANOVA (B). (D and E) Quantification of control or248 Neuron 54, 245–262, April 19, 2007 ª2007 Elsevier Inc.
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SHP-2 in Neural Precursor CellsRESULTS
SHP-2 Is Necessary for Cultured Cortical Precursor
Cells to Generate Neurons
To elucidate mechanisms that regulate genesis of neurons
versus astrocytes, we examined primary murine E12 cor-
tical precursors, a system we characterized previously
(Me´nard et al., 2002; Barnabe´-Heider and Miller, 2003;
Barnabe´-Heider et al., 2005). Upon plating in FGF2, these
precursors are dividing, nestin-positive cells that generate
neurons first at 1 day in vitro (DIV) and glia at 5–6 DIV. This
increase in differentiated cells is accompanied by deple-
tion of proliferating precursors.
We showed previously that cortical precursor neuro-
genesis requires activation of an MEK-C/EBP signaling
pathway (Me´nard et al., 2002; Barnabe´-Heider and Miller,
2003; Paquin et al., 2005), whereas astrocyte formation
requires cardiotrophin-1-mediated gp130-JAK-STAT
activation (Barnabe´-Heider et al., 2005). Because SHP-2
can regulate these two signaling cascades, we asked
whether it regulates cell-fate decisions in cortical precur-
sors. Initially, we showed that SHP-2 is expressed in
cortical precursors and newly born cortical neurons by
western blots (Figure 1A) and immunocytochemistry (Fig-
ure 1B). We then characterized SHP-2 expression in the
embryonic cortex by immunocytochemistry. During the
neurogenic period, at E12 and E15, SHP-2 was enriched
in nestin-positive precursors of the ventricular/subventric-
ular zones (VZ/SVZ) relative to neurons in the cortical plate
(Figure 1C). By E17, when gliogenesis commences, the
highest relative levels of SHP-2 were in neurons of the cor-
tical mantle, with lower expression in the VZ/SVZ. A similar
expression pattern was observed at P5 (Figure 1C). Thus,
SHP-2 is relatively high in neurogenic versus gliogenic
cortical precursors.
To ask if SHP-2 was necessary for neurogenesis, we
used two different SHP-2 shRNAs. We determined the ef-
ficacy of these shRNAs by transfection into NIH-3T3 cells.
Western blots showed that SHP-2 levels were reduced by
both SHP-2 shRNAs at 48–72 hr posttransfection even
though only 30% of the 3T3 cells were transfected (Fig-
ure 1D; data not shown). We then cotransfected cortical
precursors with EGFP and the SHP-2 shRNAs and ana-
lyzed SHP-2 levels immunocytochemically at 2 DIV;shRNA1 and shRNA2 both reduced SHP-2 levels, with
shRNA1 being the more effective of the two (Figures 1E
and 1F; data not shown). We then performed similar ex-
periments and asked if SHP-2 knockdown affected neuro-
genesis by immunostaining for the neuron-specific protein
bIII-tubulin at 3 DIV (Figure 2A). Quantification revealed
that SHP-2 shRNA1 and shRNA2 both decreased the
number of transfected neurons (Figure 2B). To confirm
that this was due to decreased SHP-2 levels, we per-
formed a rescue experiment. Precursors were cotrans-
fected with SHP-2 shRNA1 and HA-tagged human SHP-
2 (which would not be targeted by the murine shRNA)
and analyzed 3 days later for bIII-tubulin. The human
SHP-2 completely rescued the decreased neurogenesis
caused by murine SHP-2 shRNA (Figure 2B).
Although these data support the idea that SHP-2 is re-
quired for neurogenesis, alternative explanations are that
SHP-2 is necessary for precursor proliferation or survival.
To address these possibilities, precursors were cotrans-
fected with EGFP and SHP-2 shRNA1, shRNA2, or scram-
bled shRNA and were analyzed immunocytochemically
at 2 DIV for Ki67, to monitor proliferation, or cleaved
caspase-3, to monitor apoptosis. Quantification revealed
that the SHP-2 shRNAs had no significant effect on prolif-
eration (Figure 2C) or apoptosis (Figure 2D) of transfected
precursors. Counts of uncondensed Hoechst-positive nu-
clei confirmed that SHP-2 knockdown had no effect on
survival (Figure 2E). As a final control, we performed sim-
ilar experiments in the presence of the pan-caspase inhib-
itor ZVAD, which completely inhibits apoptosis of cortical
precursors (data not shown); SHP-2 shRNA still reduced
the percentage of transfected neurons in the presence
of ZVAD (Figure 2F). Thus, SHP-2 is not essential for
cortical precursor survival or proliferation but is necessary
for neurogenesis.
SHP-2 Inhibits Cytokine-Mediated Genesis
of Astrocytes in Cortical Precursor Cultures
Because SHP-2 negatively regulates the JAK-STAT path-
way in some cells, we asked whether it regulates astrocyte
formation. To do this, we cotransfected precursors with
EGFP and SHP-2 shRNA1, shRNA2, or scrambled shRNA
and then induced premature astrogenesis with exogenous
CNTF (Johe et al., 1996; Bonni et al., 1997) at 2 DIV.DP-SHP-2-transfected cells expressing (D) GFAP or (E) bIII-tubulin. In (D), cells were exposed to CNTF at 2 DIV and immunostained 3 days later, and in
(E), cells were immunostained after 3 DIV. **p < 0.01, ***p < 0.005.
(F–L) Clonal analysis demonstrates that SHP-2 instructs precursor cells to generate neurons at the expense of astrocytes. (F) Immunocytochemistry
for EGFP (GFP; green), bIII tubulin (blue), and GFAP (red) in precursors cotransfected with EGFP and SHP-2 shRNA1, exposed to 50 ng/ml CNTF at 2
DIV and cultured 4 more days. Arrows and arrowheads denote EGFP-positive astrocytes and neurons, respectively. Space bar, 50mm. (G) Quanti-
fication of three pooled experiments similar to (F) where precursors were exposed to CNTF at 2 DIV and analyzed 2 days later. *p < 0.05, **p <
0.01. (H) Quantification of two experiments of three similar to (F), where cortical precursors were cultured 4 or 6 DIV in the absence of CNTF. (I) Im-
munocytochemistry of precursors cotransfected with EGFP (green) and SHP-2 shRNA1 for 2 days, exposed to CNTF for 2 days, and then stained for
bIII-tubulin (blue) and GFAP (red). Arrows indicate the same transfected precursor coexpressing all three proteins. Scale bar, 25 mm. (J) Quantification
of two pooled experiments (of three) similar to (I), where cells were cultured in the presence of ZVAD from day 1 on. Cells were double labeled for bIII-
tubulin and EGFP. *p < 0.05. (K) Quantification of the percentage of neurogenic and gliogenic clones in experiments similar to (F), where cells were
cotransfected with EGFP and empty vector or D61G SHP-2, showing pooled data from four independent experiments. *p < 0.05, **p < 0.01. (L) Quan-
tification of two experiments (of three) similar to (J) except that precursors were cotransfected with EGFP and scrambled vector or D61G SHP-2.
Error bars denote SEM in all cases.Neuron 54, 245–262, April 19, 2007 ª2007 Elsevier Inc. 249
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SHP-2 in Neural Precursor CellsImmunocytochemistry 4 days later (6 DIV) for GFAP (Fig-
ure 3A) demonstrated that SHP-2 shRNA1 and shRNA2
robustly increased the number of transfected astrocytes
(Figure 3B). Similar results were obtained with the early as-
trocyte/astrocyte precursor marker CD44 (Figure 3C) (Liu
et al., 2004; Barnabe´-Heider et al., 2005), indicating that
SHP-2 normally functions to inhibit cytokine-mediated
astrogenesis.
To ask whether this inhibition of astrogenesis required
SHP-2 phosphatase activity, we used a dominant-nega-
tive SHP-2 mutant, DP-SHP-2, that has a 30 nucleotide
deletion in the phosphatase domain (Tang et al., 1995).
Precursors were cotransfected with EGFP and DP-
SHP-2, exposed to CNTF at 2 DIV, and immunostained
for GFAP at 6 DIV. This analysis revealed that, as seen
with SHP-2 shRNAs, DP-SHP-2 enhanced CNTF-medi-
ated astrocyte formation (Figure 3D). We therefore asked
whether the neurogenic effects of SHP-2 also required
phosphatase activity; precursors were transfected with
DP-SHP-2 and 3 days later were immunostained for bIII-
tubulin. These experiments demonstrated that DP-SHP-
2 had no effect on the numbers of transfected neurons
(Figure 3E), suggesting that SHP-2 regulates neurogene-
sis via a nonphosphatase-dependent mechanism.
SHP-2 Instructs Cortical Precursors to Generate
Neurons versus Astrocytes
To ask whether SHP-2 mediates these effects on cortical
precursor differentiation by instructing precursors to gen-
erate neurons rather than astrocytes, we performed clonal
analysis; individual precursors were transfected at very
low densities with EGFP and SHP-2 shRNA1, CNTF was
added at 2 DIV, and cultures were immunostained at 4
DIV for EGFP, bIII-tubulin, and GFAP. Alternatively, exper-
iments were performed in the absence of CNTF. In either
case, isolated, EGFP-positive clones of cells were ana-
lyzed for their composition (Figure 3F); clones containing
at least one bIII-tubulin positive neuron but no astrocytes
were classified as neuronal clones, those containing at
least one GFAP-positive astrocyte but no neurons as as-
trocyte clones, and those containing both neurons and
astrocytes as bipotent clones. Clones containing no cells
expressing either of these markers were also observed.
This analysis revealed that, in the presence of CNTF,
SHP-2 knockdown decreased the number of neuronal
clones and increased the number of astrocyte clones
(Figure 3G). Bipotent clone numbers were unchanged
(4%–5% with or without SHP-2 shRNA; p > 0.05), and
clone size was unaffected (p > 0.05). In the absence of
CNTF, SHP-2 knockdown reduced the number of neuro-
nal clones and caused premature genesis of astrocyte
clones at 4 and 6 DIV (Figure 3H). Thus, endogenous
SHP-2 instructs precursors to generate neurons at the
expense of glia.
This triple-label analysis also revealed one unexpected
result: although control transfected cells never coex-
pressed neuronal and astrocytic proteins, SHP-2 knock-
down caused the appearance of a small number of appar-250 Neuron 54, 245–262, April 19, 2007 ª2007 Elsevier Inc.ently ‘‘confused’’ cells that expressed both bIII-tubulin and
GFAP in the presence of CNTF (Figure 3I). We therefore
ensured that the observed decrease in neuronal clones
was not due to cell death by performing clonal experi-
ments in the presence of ZVAD. Immunocytochemistry
confirmed that SHP-2 shRNA1 decreased the number of
neuronal clones in the presence or absence of ZVAD
(Figure 3J). Thus, endogenous SHP-2 ensures (1) that
precursors become neurons rather than astrocytes and
(2) that precursors do not attempt to adopt both fates in re-
sponse to extrinsic cues.
An NS SHP-2 Mutant Promotes Neurogenesis
and Inhibits Gliogenesis from Cultured
Cortical Precursors
In 50% of NS patients, the disorder is due to missense mu-
tations that enhance the activity of SHP-2 (Tartaglia et al.,
2001; Fragale et al., 2004; Yoshida et al., 2004). D61G
SHP-2 is one such mutation seen in 10% of NS patients
(Yoshida et al., 2004). To ask if an NS SHP-2 mutant
would alter cortical precursor cell-fate decisions, we co-
transfected precursors with HA-tagged D61G SHP-2,
HA-tagged wild-type (WT) SHP-2, or EGFP as a control.
Immunocytochemistry and quantification 3 days later (Fig-
ures 4A and 4B) revealed that both D61G and WT SHP-2
increased the percentage of transfected bIII-tubulin-posi-
tive cells (Figure 4B). We then asked whether this increase
was due to increased proliferation and/or survival of newly
born neurons as opposed to enhanced neurogenesis. Im-
munocytochemistry for Ki67 at 2 DIV (Figure 4C) revealed
that D61G SHP-2 modestly decreased proliferation, con-
sistent with enhanced neurogenesis. Analysis of Hoechst-
positive apoptotic nuclei demonstrated that WT and
D61G SHP-2 had no effect on neuronal survival but pro-
moted a small increase in survival of bIII-tubulin-negative
cortical precursors (Figures 4D and 4E). This small survival
effect did not contribute to the observed increase in neu-
rogenesis, because D61G SHP-2 increased the percent-
age of neurons to a similar extent in the presence or
absence of ZVAD (Figure 4F).
These data indicate that increased levels or activity of
SHP-2 directly promote neurogenesis. We therefore
asked whether the NS SHP-2 D61G mutant perturbed
gliogenesis. Precursors were transfected as in the neuro-
genesis experiments and exposed to CNTF at 2 DIV.
Immunocytochemistry at 6 DIV revealed that D61G SHP-
2 decreased the genesis of transfected, GFAP-positive
astrocytes (Figures 4G and 4H), whereas overexpression
of WT SHP-2 had no effect (Figure 4H). Thus, SHP-2
inhibits astrogenesis as it enhances neurogenesis.
Finally, we asked whether these changes were due to
altered cell-fate decisions by performing clonal analysis.
Precursors were cotransfected at very low density with
D61G SHP-2 and EGFP and exposed to CNTF at 2 DIV,
and clones were then analyzed at 6 DIV (Figure 3K). Immu-
nocytochemistry revealed that D61G SHP-2 increased the
number of neuronal clones and concomitantly decreased
the number of astrocyte clones. D61G SHP-2 did not
Neuron
SHP-2 in Neural Precursor CellsFigure 4. An NS-Activated SHP-2 Mutant Promotes Neurogenesis and Inhibits Gliogenesis in Cultured Cortical Precursors
(A) Immunocytochemistry for HA (green) and bIII-tubulin (red) in precursors transfected with HA-tagged D61G SHP-2 and cultured 3 DIV. Cells were
counterstained with Hoechst 33258. Arrow denotes a double-labeled, transfected cell.
(B) Quantification of transfected, bIII-tubulin-positive neurons in experiments similar to (A), where precursors were cotransfected with EGFP and WT
or D61G SHP-2. **p < 0.01, ANOVA.
(C) Quantification of precursors transfected as in (A), cultured 2 DIV, and immunostained for Ki67. Three pooled experiments are shown. **p < 0.01.
(D and E) Quantification of precursors transfected as in (B), cultured 2 DIV, immunostained for EGFP and bIII-tubulin, and counterstained with Hoechst
33258 to monitor nuclear morphology. (D) shows the percentage of live cells in two independent experiments, whereas (E) shows the percentage of
bIII-tubulin-positive and -negative cells with normal (live) versus apoptotic (dead) nuclear morphology within an individual experiment. *p < 0.05,
**p < 0.01.
(F) Quantification of one of two experiments as in (A), where precursors were cultured in the presence of ZVAD. **p < 0.01, Student’s t test.
(G) Immunocytochemistry for HA (green) and GFAP (red) in precursors transfected with HA-tagged D61G SHP-2, exposed to 50 ng/ml CNTF at 2 DIV,
and cultured 4 more days. Cells were counterstained with Hoechst 33258. Arrowheads denote a transfected cell that is GFAP negative.
(H) Quantification of transfected, GFAP-positive astrocytes in two experiments (of six) similar to (G). *p < 0.05, **p < 0.01, ANOVA.
Error bars denote SEM in all cases.Neuron 54, 245–262, April 19, 2007 ª2007 Elsevier Inc. 251
Neuron
SHP-2 in Neural Precursor Cells252 Neuron 54, 245–262, April 19, 2007 ª2007 Elsevier Inc.
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SHP-2 in Neural Precursor Cellsaffect the number of bipotent clones (3% in both cases,
p = 0.2), and clone size was unaffected (p > 0.05). Similar
results were obtained in the presence of ZVAD (Figure 3L).
Thus, D61G SHP-2 functions within individual cortical pre-
cursors to promote neurogenesis while inhibiting cyto-
kine-induced astrocyte formation.
SHP-2 Is Necessary to Promote Neurogenesis
during Embryonic Cortical Development In Vivo
To ask whether SHP-2 plays a similar role in vivo, we
performed in utero electroporation to knockdown SHP-2
expression in precursors of the VZ/SVZ of the embryonic
cortex (Barnabe´-Heider et al., 2005; Paquin et al., 2005).
We previously demonstrated that 1 day after in utero elec-
troporation at E13/14, all of the transfected cells reside in
the VZ/SVZ and 85% of these cells are proliferating
(Paquin et al., 2005). Many of these transfected cells dif-
ferentiate into neurons over the next few days, and these
neurons migrate out of the VZ/SVZ into the cortical plate.
Some of the transfected cells also remain in the VZ/SVZ,
where they adopt an astrocyte fate during the early post-
natal period.
We therefore performed in utero electroporation at E13/
14 with plasmids encoding a nuclear EGFP and SHP-2
shRNA1 or scrambled shRNA and analyzed the cortex
3–4 days later. Immunocytochemistry for EGFP revealed a
robust difference between control and SHP-2 shRNA1-
transfected brains, with approximately twice as many
control transfected cells migrating out of the VZ/SVZ into
the cortical mantle (which includes both the intermediate
zone of migrating neurons and the cortical plate [Figures
5A and 5B]). Moreover, quantitative confocal analysis of
sections immunostained for the neuronal protein HuD
revealed that many more of the control, scrambled
shRNA-transfected cells were HuD-positive neurons at
this time point (Figures 5C and 5D). In both SHP-2 shRNA1
and scrambled shRNA-transfected cells, these HuD-pos-
itive neurons were located in the cortical mantle. By immu-
nostaining for the early neuronal protein bIII-tubulin, we
demonstrated that only small numbers of newly born neu-
rons were present within the VZ/SVZ and that these num-
bers were similar in both conditions (data not shown).Thus, SHP-2 knockdown decreased the genesis of corti-
cal neurons in vivo as it did in culture.
To rule out the possibility that the decrease in neurons
was due to enhanced cell death and/or altered prolifera-
tion, we analyzed adjacent sections for cleaved cas-
pase-3 and Ki67. Analysis for cleaved caspase-3 revealed
only rare double-labeled cells in control and experimental
brains (Figure 5E; less than ten cells per brain in both
cases). Similarly, the percentage of transfected Ki67-
positive cells, which were located only in the VZ/SVZ, was
similar in control and SHP-2 shRNA1-transfected brains
at both 3 and 4 days postelectroporation (Figures 5F and
5G). Thus, SHP-2 knockdown had no effect on survival
or proliferation but specifically inhibited neurogenesis.
SHP-2 Knockdown Leads to Premature Gliogenesis
in the Embryonic Cortex
Because the culture data indicated that endogenous SHP-
2 instructs precursors to make neurons rather than glia,
we asked if it inhibited gliogenesis during the embryonic
neurogenic period in vivo. To do this, embryos were elec-
troporated with EGFP and SHP-2 shRNA1 at E13/E14 and
analyzed 3 or 4 days later by double labeling for GFP and
GFAP. At E16/17 (3 days postelectroporation), no GFAP-
positive cells were detected in cortices transfected with
control, scrambled shRNA, but a small number of trans-
fected astrocytes were present in cortices transfected
with SHP-2 shRNA1 (Figure 6A). By E17/18, some GFAP-
positive astrocytes were observed in control cortices, but
none of these were derived from transfected precursors in
the three brains that were analyzed (Figure 6B). In con-
trast, SHP-2 shRNA-transfected, GFAP-positive astro-
cytes were observed at this time point (Figure 6B). Thus,
genetic knockdown of SHP-2 leads to precocious astro-
cyte formation during the late neurogenic period.
To quantitatively assess this enhanced gliogenesis, we
performed similar electroporations and counted trans-
fected, GFAP-positive cells within the SVZ at P3 (Fig-
ure 6C). This analysis (Figure 6D) revealed that when
SHP-2 was knocked down, the number of transfected as-
trocytes increased by 3-fold. Because our culture data
also indicated that the phosphatase activity of SHP-2
was essential for its gliogenic effects, we performedFigure 5. Genetic Knockdown of SHP-2 Inhibits Cortical Neurogenesis In Vivo
Precursor cells of the E13/E14 cortex were electroporated with EGFP and SHP-2 shRNA1 or scrambled shRNA and analyzed 4 days later.
(A) Immunocytochemistry for EGFP (GFP; green) in coronal cortical sections. Sections were counterstained with Hoechst 33258. h, hippocampus;
VZ, ventricular zone; SVZ, subventricular zone; and CM, cortical mantle. Scale bar, 100 mm.
(B) Quantification of GFP-positive cells that migrated to the cortical mantle in experiments similar to (A). For 4 days, n = 6 each. ***p < 0.005.
(C) Confocal images of a section through the cortical plate double labeled for EGFP (GFP; green) and HuD (red). Arrows denote transfected, double-
labeled cells. Scale bar, 20 mm.
(D) Quantification of transfected, HuD-positive cells in cortices electroporated with SHP-2 shRNA1 or scrambled shRNA in experiments similar to (C).
For 4 days, n = 6 brains each. ***p < 0.005.
(E) Micrographs of a section double labeled for EGFP (GFP) and cleaved caspase-3 (red), and counterstained with Hoechst 33258. Arrow denotes
a rare, transfected caspase-3-positive cell. Scale bar, 50 mm.
(F) Confocal micrographs of the VZ/SVZ of sections double labeled for EGFP (GFP; green) and Ki67 (red). Arrows denote double-labeled cells. Scale
bar, 20 mm.
(G) Quantification of transfected, Ki67-positive cells in the VZ/SVZ of sections similar to (F). p > 0.05.
Error bars denote SEM in all cases.Neuron 54, 245–262, April 19, 2007 ª2007 Elsevier Inc. 253
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SHP-2 in Neural Precursor CellsFigure 6. Inhibition of SHP-2 Perturbs the Timing and Magnitude of Gliogenesis In Vivo
(A–D) Precursor cells of the E14 cortex were electroporated with EGFP and SHP-2 shRNA1 or scrambled shRNA and analyzed at E17 (A), E18 (B), or
P3 (C and D) by immunocytochemistry for EGFP (GFP; green) and GFAP (red). (A and B) Micrographs of coronal sections through the E17 (A) or E18 (B)
SVZ transfected with SHP-2 shRNA1 or scrambled shRNA at E14. (C) Confocal images of the SVZ in cortices transfected at E14 and analyzed at P3. In254 Neuron 54, 245–262, April 19, 2007 ª2007 Elsevier Inc.
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SHP-2 in Neural Precursor Cellssimilar experiments with DP-SHP-2; DP-SHP-2 increased
the percentage of astrocytes that were generated by 2- to
3-fold, as monitored by immunocytochemistry for either
GFAP or CD44 (Figures 6E and 6F). We also analyzed neu-
rogenesis in the DP-SHP-2-transfected brains 4 days
postelectroporation and observed, as we had seen in cul-
ture, that it had no effect on the number of transfected,
HuD-positive neurons (Figure 6G). Thus, SHP-2 normally
regulates the onset and extent of astrogenesis in vivo.
SHP-2 Knockdown in the Embryonic Period Leads
to Postnatal Perturbations in Cortical Neurons
Although the perturbations in neonatal gliogenesis after
SHP-2 knockdown were localized to the SVZ, analysis of
the remainder of the cortex revealed additional perturba-
tions. In particular, although the percentage of transfected
cells present in the SVZ versus the cortical layers was sim-
ilar in scrambled shRNA and SHP-2 shRNA1-transfected
cortices (Figures 6H and 6I), cell location within the cortical
layers differed. The majority (95%) of control transfected
cells were present in cortical layers II and III, but 65%
of the SHP-2 shRNA1-transfected cells were scattered
throughout layers IV–VI (Figure 6I). These misplaced cells
were not glia, because all of the transfected cells express-
ing GFAP or a marker for oligodendrocytes, O4, were in
the SVZ (data not shown). Instead, the large majority of
the SHP-2 shRNA1-transfected cells within the cortical
layers were neurons, as defined by HuD immunostaining
(Figures 6J and 6K). Thus, by P3, the percentage of trans-
fected cortical neurons was similar with scrambled shRNA
versus SHP-2 shRNA1, but SHP-2 shRNA1-transfected
neurons were inappropriately located. Because these
experiments involved transient transfections, SHP-2
knockdown may be less efficient at later time points,
with neurons ultimately being generated from ‘‘delayed’’
precursors between E17/18 and P3 and then migrating in-
appropriately due to their late birth date. Alternatively,
these data may indicate that SHP-2 plays a direct role in
the migration of newly born neurons.
An NS SHP-2 Mutant Promotes Neurogenesis
and Inhibits Gliogenesis in the Developing Cortex
To ask whether the NS SHP-2 D61G mutation causes
cell-fate perturbation in the embryonic brain as it does in
culture, we performed in utero electroporation at E13/14with plasmids encoding nuclear EGFP and the D61G
SHP-2 mutant or WT SHP-2. Immunocytochemistry and
quantitative confocal microscopy for HuD 3 or 4 days later
revealed an increase in the number of D61G SHP-2-trans-
fected cells that were neurons 4 days postelectroporation
(Figure 7A). These neurons were all appropriately located
within the cortical mantle. To ask whether WT SHP-2 had
the same effect, we electroporated it into the cortex of
E13/14 Ta1:nlacZ mice (Gloster et al., 1994; Paquin
et al., 2005); these mice express nuclear b-galactosidase
from the early neuron-specific promoter Ta1 a-tubulin.
Analysis 3 days later revealed that WT SHP-2 robustly in-
creased the number of newly born, Ta1:nlacZ-positive
neurons that were generated (Figure 7B). Thus, as seen
in culture, ectopic expression of either D61G or WT
SHP-2 enhanced neurogenesis in vivo.
We also asked whether the D61G SHP-2 mutant in-
hibited astrocyte formation in vivo, as it did in culture. Cor-
tices were electroporated at E14 with either D61G or WT
SHP-2 and then analyzed immunocytochemically at P3
for expression of GFAP or CD44 (Figures 7C and 7D).
Quantitative analysis of these brains (Figures 7E–7G)
revealed that D61G, but not WT, SHP-2 reduced astrocyte
formation4- to 5-fold. As seen for neurons, D61G SHP-2
did not affect the localization of these cells, because these
transfected astrocytes were located within the SVZ. Thus,
the NS D61G SHP-2 mutant promotes the genesis of neu-
rons and inhibits the genesis of astrocytes in the embry-
onic cortex.
SHP-2 Promotes Neurogenesis via Activation
of the MEK-ERK Pathway and Inhibits Gliogenesis
by Directly Suppressing the gp130-JAK-STAT
Pathway
Our data indicate that endogenous SHP-2 promotes neu-
rogenesis and inhibits gliogenesis. Because SHP-2 can
promote RTK-mediated activation of the Ras-MEK-ERK
pathway, and because we have previously shown that
MEK activity is necessary and sufficient for neurogenesis
(Me´nard et al., 2002; Barnabe´-Heider and Miller, 2003;
Paquin et al., 2005), we asked whether SHP-2 promoted
neurogenesis via MEK. Initially, we transfected precursors
with EGFP and SHP-2 shRNA1 or the D61G SHP-2 mu-
tant, immunostained them with an antibody specific to
phosphorylated, activated ERK, and counted cells with(A)–(C), arrows indicate transfected, double-labeled cells. Scale bars, 50 (A and B) or 20 (C) mm. (D) Quantification of transfected, GFAP-positive cells
in the SVZ in experiments similar to (C). n = 3 brains. ***p < 0.005.
(E and F) Quantification of experiments similar to that in (C) where embryos were electroporated at E14 with EGFP andDP-SHP-2 or empty vector and
analyzed immunocytochemically for EGFP and GFAP (E) or CD44 (F) at P3. In (E), n = 7 brains each. **p < 0.01, ***p < 0.001.
(G) Quantification of experiments similar to (E) and (F) except that brains were analyzed 4 days after electroporation by immunostaining for EGFP and
HuD. n = 2 each. p > 0.05.
(H) Coronal sections of cortices electroporated at E14 with EGFP and SHP-2 shRNA1 or scrambled shRNA and immunolabeled at P3 for EGFP (GFP;
green) and counterstained with Hoechst 33258. SVZ, subventricular zone; CL, cortical layers. Scale bar, 100 mm.
(I) Quantification of transfected cells within the cortical layers (total) or in layers II and III in experiments similar to (H). n = 3 each. ***p < 0.001.
(J) Confocal image of a section similar to those in (H) immunostained for EGFP (green) and HuD (red). The image shows both the SVZ and the deeper
cortical layers (CL). Arrows denote transfected, double-labeled neurons. Scale bar, 20 mm.
(K) Quantification of transfected, HuD-positive cells within the cortical layers. n = 3 each. p > 0.05.
Error bars denote SEM in all cases.Neuron 54, 245–262, April 19, 2007 ª2007 Elsevier Inc. 255
Neuron
SHP-2 in Neural Precursor CellsFigure 7. An NS-Associated SHP-2 Mutant Enhances Neurogenesis and Inhibits Gliogenesis In Vivo
Precursor cells of the E13/14 cortex were electroporated with EGFP and D61G SHP-2, WT SHP-2, or the empty vector and analyzed at E17/18 (A and
B) or P3 (C–G). In (B), electroporations were performed with E13/14 Ta1:nlacZ mice.256 Neuron 54, 245–262, April 19, 2007 ª2007 Elsevier Inc.
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SHP-2 in Neural Precursor Cellsbasal, high or low levels of phosphoERK expression
(Figures 7H and 7I). This analysis revealed that SHP-2
shRNA1 reduced and D61G SHP-2 increased phos-
phoERK activation (Figure 7I), indicating that SHP-2 is
essential for basal levels of ERK activity in cortical precur-
sors. We then asked if the increased MEK-ERK activation
observed with D61G SHP-2 was responsible for its ability
to promote neurogenesis; transfected precursors were
treated with a pharmacological MEK inhibitor, PD98059,
and then immunostained for bIII-tubulin 3 days posttrans-
fection (Figure 7J). We previously showed that PD98059
specifically inhibits MEK in cortical precursors and that
this has no effect on precursor cell survival or proliferation
(Barnabe´-Heider and Miller, 2003). These experiments
demonstrated that PD98059 completely blocked the
enhanced neurogenesis seen in cells transfected with
D61G SHP-2. Thus, SHP-2 regulates neurogenesis via
the MEK-ERK pathway.
Because gliogenesis in cortical precursor cultures de-
pends upon the gp130-JAK-STAT pathway (Bonni et al.,
1997; Johe et al., 1996; Barnabe´-Heider et al., 2005),
and because SHP-2 negatively regulates this signaling
pathway in some cells (Ernst and Jenkins, 2004), we asked
whether SHP-2 regulated gliogenesis via this pathway. Ini-
tially, we cotransfected precursors with EGFP and SHP-2
shRNA1, DP-SHP-2, or D61G SHP-2, exposed them to
CNTF at 2 DIV for one additional day, and then immuno-
stained them with an antibody specific for phosphory-
lated, activated STAT3 (Figure 7K). This analysis revealed
that transfection with SHP-2 shRNA1 or DP-SHP-2 in-
creased, and D61G SHP-2 decreased, the number of pre-
cursors expressing detectable phosphoSTAT3 (Figure 7L).
To ask whether SHP-2 inhibited STAT activation further
upstream at the level of JAK or gp130, we asked whether
the enhanced gliogenesis seen upon SHP-2 knockdown
was dependent upon JAK activation; precursors were co-
transfected with EGFP and shRNA1 and were inducedwith CNTF at 2 DIV for an additional 4 days with or without
the pharmacological JAK inhibitor AG490. We previously
showed that this inhibitor specifically blocks JAK activity
and astrogenesis in cortical precursors, with no effects
on survival or neurogenesis (Barnabe´-Heider et al.,
2005). Immunocytochemistry for GFAP demonstrated
that JAK inhibition completely blocked the increased glio-
genesis observed with SHP-2 shRNA1 (Figure 7M). Thus,
endogenous SHP-2 inhibits astrocyte formation by nega-
tively regulating the gp130-JAK-STAT pathway.
AnNSMouseModel Displays Perturbed Cell Genesis
in the Neonatal Forebrain and Hippocampus
Although our findings suggest that enhanced SHP-2 activ-
ity in NS could cause abnormal neural development, these
were overexpression studies, whereas in NS patients, only
one copy of the mutant allele is present. We therefore ex-
amined the brains of an NS mouse model carrying one
copy of d61g shp-2 knocked into the endogenous shp-2
locus. This mouse phenocopies several aspects of the hu-
man disorder (Araki et al., 2004), but its nervous system
has not yet been examined. We therefore analyzed the
cortex and hippocampus of newborn NS mice, at a time
when astrogenesis had just started (Figure 8A). Initially,
we examined coronal sections through the dentate gyrus
of SHP-2 D61G/+ mice versus their WT littermates and
age-matched nonlittermates (Figure 8A, region 1). These
sections were immunostained for the astrocyte marker
GFAP (Figure 8B) or the neuronal marker HuD and coun-
terstained with Hoechst 33258 (Figure 8B) to allow quan-
tification of total neurons, astrocytes, cell numbers, and
tissue area. These parameters were then quantified in
three to four coronal sections per brain at the same rostral-
caudal level of the dentate gyrus (Figures 8A and 8B).
This analysis revealed significant differences between
the hippocampus of WT versus NS mice. Counts of total
Hoechst-positive nuclei revealed that cell density was(A) Quantification of transfected, HuD-positive neurons in E17/18 coronal cortical sections immunostained for EGFP and HuD. n = 3 control and
4 experimental brains. *p < 0.05.
(B) Quantification of transfected, Ta1:nlacZ-positive cells 3 days after electroporation, as detected by immunocytochemistry for EGFP and b-galac-
tosidase. n = 2 each. ***p < 0.005.
(C and D) Confocal micrographs of coronal sections through the SVZ of P3 brains double labeled for EGFP (GFP; green) and GFAP ([C], red) or CD44
([D], red). Arrows denote double-labeled cells. Scale bar, 20 mm.
(E–G) Quantification of transfected, GFAP-positive (E and F) or CD44-positive (G) cells within the SVZ in experiments similar to (C). In (E), n = 7 and 6; in
(F), n = 4 and 5; and in (G), n = 2 each of experimental and control brains. *p < 0.05, **p < 0.01.
(H–J) An NS-associated SHP-2 mutant enhances neurogenesis via MEK. (H) Immunocytochemistry for EGFP (GFP; green) and phosphorylated ERK
(phosphoERK; red) in precursors cotransfected with EGFP and D61G SHP-2 and cultured 3 DIV. Arrows and the dotted arrow denote transfected cells
that express high or basal levels of phosphoERK, respectively. Scale bar, 25 mm. (I) Quantification of transfected, phosphoERK-positive cells in one of
two experiments where precursors were cotransfected with EGFP plus D61G SHP-2 or SHP-2 shRNA1. *p < 0.05, ANOVA. (J) Quantification of trans-
fected, bIII-tubulin-positive cells in three independent experiments where precursors were transfected with EGFP or HA-tagged D61G SHP-2, treated
with PD98059 or DMSO after 1 DIV, and analyzed 2 days later. *p < 0.05, **p < 0.01, ANOVA.
(K–M) SHP-2 inhibits gliogenesis by negatively regulating gp130-JAK-STAT signaling. (K) Immunocytochemistry for EGFP (GFP; green) and phospho-
STAT-3 (red) in precursors cotransfected with EGFP and SHP-2 shRNA1, treated with 50 ng/ml CNTF at 2 DIV and cultured one more day. Cultures
were counterstained with Hoechst 33258. The arrow indicates a double-labeled cell. Scale bar, 50 mm. (L) Quantification of transfected, phospho-
STAT-3-positive cells in one of three experiments similar to (K). Cultures were cotransfected with plasmids encoding EGFP and SHP-2 shRNA1,
scrambled shRNA, DP-SHP-2, or D61G SHP-2. *p < 0.05, ANOVA. (M) Quantification of transfected, GFAP-positive cells in two experiments where
precursors were cotransfected with EGFP and SHP-2 shRNA1 or scrambled shRNA and treated at 2 DIV with 50 ng/ml CNTF with or without AG490
for 4 more days prior to immunostaining for EGFP and GFAP. *p < 0.05, **p < 0.01, ANOVA.
Error bars denote SEM in all cases.Neuron 54, 245–262, April 19, 2007 ª2007 Elsevier Inc. 257
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SHP-2 in Neural Precursor Cellssignificantly increased (6%) in NS mice (Figure 8C).
Quantification of HuD-positive neurons in the same area
also revealed a small but significant increase in both the
density and percentage of neurons (Figure 8D). However,
the most robust phenotype was revealed when GFAP-
positive astrocytes were quantificated; both the density
and the percentage of total cells that were astrocytes
were decreased by 2.5- to 3-fold in the NS hippocampus
(Figures 8B and 8E).
Similar changes were seen in the dorsal cortex
(Figure 8A, region 2) of WT versus NS brains that were an-
alyzed at postnatal day 2. The density of total cells dis-
played a small but significant increase (Figures 8F and
8I), and the density and percentage of NeuN-positive neu-
rons also showed a small but significant increase (Figures
8F and 8J). In addition, quantification of GFAP-positive
cells within the SVZ demonstrated a 2-fold decrease in
the density and percentage of astrocytes in the NS versus
WT cortex (Figures 8G and 8K). The intensity of GFAP im-
munostaining in the glia limitans at this level was also re-
duced in the neonatal NS brains (Figure 8H). Thus, in
both the dorsal cortex and hippocampus of neonatal NS
mice, there is a large decrease in astrocytes and a small
but significant increase both in total cellular and neuronal
density, alterations that may contribute to further pertur-
bations during circuit formation and that ultimately could
lead to cognitive dysfunction.
DISCUSSION
The data presented here support three major conclusions.
First, the experiments using SHP-2 shRNA indicate that
endogenous SHP-2 is essential for the normal genesis of
cortical neurons and astrocytes both in culture and within
the environment of the embryonic cortex. Genetic knock-
down of SHP-2 leads to a delay in neurogenesis and ulti-
mately a perturbation in neuronal location. It also causes
inappropriate precocious formation of astrocytes during
the embryonic neurogenic period and leads to a robust in-
crease in the number of astrocytes generated. Second, asshown in the clonal experiments, SHP-2 mediates these
effects by instructing neural precursors to generate neu-
rons rather than astrocytes, thereby ensuring that precur-
sors that are biased to a neuronal fate do not attempt to
become glia even in the presence of cytokines. This oc-
curs via two dissociable mechanisms: SHP-2 activates
the neurogenic Ras-MEK-C/EBP pathway and at the
same time inhibits the gliogenic gp130-JAK-STAT path-
way. Third, the constitutive activation of SHP-2 that oc-
curs in NS causes a large reduction in astrocyte formation
and a coincident small increase in neuronal number in the
forebrain and hippocampus of mice. These effects are
seen both after ectopic expression of an NS shp-2 allele
and, importantly, in an NS mouse model carrying the
same activated allele in place of the WT allele, as occurs
in humans. Together these data indicate that SHP-2 regu-
lates the timing and extent of neurogenesis versus glio-
genesis by acting as a growth factor-regulated switch to
bias cortical precursor cells toward one fate and against
another. Perturbations in the ratio of neurons versus glia
as a result of constitutive SHP-2 activation may contribute
to the cognitive dysfunction observed in NS individuals.
During development of the mammalian nervous system,
cell genesis is a timed event, with neurons generated first
and glial cells second. Within the murine cortex, these
neurogenic and gliogenic periods are temporally distinct:
neurogenesis occurs from E12-E17, whereas astrocyte
formation is largely postnatal. Many of the previous stud-
ies examining how growth factors regulate this timer have
focused upon positive, inductive mechanisms (reviewed
in Pearson and Doe [2004] and Guillemot et al. [2006]).
Here, we show that appropriately timed gliogenesis also
depends upon an SHP-2-mediated suppressive signal
that inhibits competent precursors from prematurely gen-
erating astrocytes. We propose that, during the embryonic
neurogenic period, SHP-2 is an integral upstream compo-
nent of the neurogenic RTK-MEK-ERK-C/EBP pathway.
At the same time, SHP-2 suppresses the low levels of
gliogenic gp130-JAK-STAT signaling that may occur in
response to cytokines such as neuropoietin 1 andFigure 8. An NS Mouse Model Shows Enhanced Neurogenesis and Decreased Gliogenesis in the Neonatal Hippocampus and
Cortex
(A) Coronal section through the neonatal forebrain, depicting the regions that were analyzed in the hippocampus (region 1) and dorsal cortex (region 2).
(B–E) Analysis of the P0 dentate gyrus (region 1). In all cases, at least three adjacent sections through this region were analyzed per brain. (B)
Immunocytochemistry for GFAP (red) in coronal dentate gyrus sections at the same rostral-caudal level of the P0 NS (D61G/+) or WT (+/+) brain.
Cell density was determined by counterstaining with Hoechst 33258 (white or blue). Dashed outline represents the area that was analyzed. Arrows
denote GFAP-positive cells. Scale bar, 50 (top) and 25 mm (bottom). (C) Quantification of mean cell density in the area denoted in (B). n = 6 and 5,
control and NS brains. *p < 0.05. (D) Quantification of mean HuD-positive cell density (left panel) and percentage of HuD-positive cells/total cells (right
panel) in the area denoted in (B). n = 6 and 5, control and NS brains. *p < 0.05, ***p < 0.005. (E) Quantification of mean GFAP-positive cell density (left
panel) and the percentage of GFAP-positive cells/total cells (right panel) in the area denoted in (B). n = 6 brains each. ***p < 0.005.
(F–K) Analysis of the postnatal day 2 (P2) dorsal cortex (region 2). In all cases, at least four adjacent sections through this region were analyzed per
brain. (F) Immunocytochemistry for NeuN (green) in coronal sections at the same rostral-caudal level of the P2 NS (D61G/+) or WT (+/+) brain. Cell
density was determined by counterstaining with Hoechst 33258 (white). CP, cortical plate. Scale bar, 100mm. (G and H) Immunocytochemistry for
GFAP (red) in the SVZ (G) or glia limitans (H) in the dorsal cortex of P2 NS (D61G/+) versus WT (+/+) brains. Arrows denote GFAP-positive cells. Scale
bar, 50 mm. (I) Quantification of mean total cell density in sections similar to (F). n = 2 brains each. *p < 0.05. (J) Quantification of mean NeuN-positive
cell density (left panel) and the percentage of NeuN-positive cells/total cells (right panel) in sections similar to (F). n = 2 brains each. *p < 0.05,
***p < 0.005. (J) Quantification of mean GFAP-positive cell density (left panel) and the percentage of GFAP-positive cells/total cells (right panel) in
the SVZ in sections similar to (G). n = 3 and 2, control and NS brains. ***p < 0.005.
Error bars denote SEM in all cases.Neuron 54, 245–262, April 19, 2007 ª2007 Elsevier Inc. 259
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SHP-2 in Neural Precursor Cellscardiotrophin-like cytokine that are expressed in the em-
bryonic brain (Uemura et al., 2002; Derouet et al., 2004).
As development proceeds, newly born cortical neurons
synthesize and secrete cardiotrophin-1 (Barnabe´-Heider
et al., 2005) and cortical precursors become sensitized
to cytokines via a variety of intrinsic mechanisms (re-
viewed in Pearson and Doe [2004] and Guillemot et al.
[2006]). Under these new conditions, SHP-2 does not
completely suppress gliogenesis but instead regulates
the number of astrocytes that are generated by attenuat-
ing gp130-JAK-STAT signaling. Thus, SHP-2 functions
as an essential component of growth factor-regulated sig-
naling mechanisms that determine the timing and extent
of neurogenesis versus gliogenesis in the developing
cortex.
An equally important major conclusion of this study is
that enhanced SHP-2 activity in NS causes perturbations
in cortical cell-fate decisions, leading to a small increase in
neurogenesis and a robust decrease in gliogenesis. We
observed these perturbations in a mouse model of NS
that phenocopies the human condition with regard to all
parameters so far examined (Araki et al., 2004). Moreover,
our in utero electroporation studies argue that many of
these effects are cell autonomous, with the d61g shp-2
allele directly perturbing precursor cell-fate decisions.
We suggest that these perturbations in cell genesis during
early development could lead to subsequent alterations in
cell survival and/or circuit formation, thereby substantively
impacting cognitive function. As one example of such am-
plification, astrocyte development is perturbed in mice
lacking the EGF receptor, and this ultimately causes dra-
matic degeneration of forebrain neurons (Wagner et al.,
2006). Thus, genetic perturbations such as those seen in
NS, or perhaps even in more commonly studied disorders
such as Rett Syndrome, might first perturb cell genesis
and then this might in turn alter many later aspects of neu-
ral development, ultimately resulting in impaired circuitry
and cognitive dysfunction. Such a model does not pre-
clude the importance of later perturbations that might
occur in neuronal circuits as a direct consequence of ac-
tivated SHP-2, it simply argues that earlier impairments
such as altered cell genesis could have more widespread
effects because they occur so early during development.
We provide strong evidence for perturbed neural devel-
opment in a mouse model of NS. Do similar perturbations
occur in the human syndrome? Although it is clear that
many of these individuals display learning disabilities
and mental retardation (Noonan, 1994; Yoshida et al.,
2004; Jongmans et al., 2005; Lee et al., 2005), there
have only been a few anatomical/imaging studies re-
ported. However, those few studies do indeed indicate
that there are perturbations, including cortical dysplasia,
cortical atrophy, and cerebellar malformations (Saito
et al., 1997; Gorke, 1980; Peiris and Ball, 1982; Heye
and Dunne, 1995). Because the mouse model that we
studied here has been shown to phenocopy the human
condition with regard to more well-studied aspects of
the syndrome such as craniofacial abnormalities, cardiac260 Neuron 54, 245–262, April 19, 2007 ª2007 Elsevier Inc.defects, and myeloproliferation, we believe that neural de-
fects similar to those documented here are likely to occur
in the human condition. In this regard, Costello and cardio-
facial-cutaneous (CFC) syndromes, which are in the same
family of genetic disorders as NS and display mental retar-
dation, have recently been shown to arise from activating
mutations in the HRas-BRaf-MEK-ERK pathway (Ben-
tires-Alj et al., 2006). Thus, we propose that the SHP-2-
MEK-ERK-C/EBP pathway we have defined as important
for neural cell-fate determination is essential for normal
human brain development.
Little is known about how genetic perturbations lead to
mental retardation. Here, we have identified a signaling
protein, SHP-2, that plays a key role in allowing environ-
mental cues such as growth factors to instruct multipotent
precursor cells to generate one cell type versus another.
Moreover, we have shown that the same constitutively
activated SHP-2 that occurs in a subpopulation of NS
patients causes aberrant neural development in mice,
providing a potential explanation for the cognitive dys-
function and neuroanatomical perturbations observed in
this disorder. Such a mechanism may well generalize to
other syndromes where signaling pathways that are im-
portant for neural cell genesis are genetically perturbed.
EXPERIMENTAL PROCEDURES
Cell Cultures, Inhibitor Treatments, and Transfections
E11.5–12.5 cortical precursors were cultured in 40 ng/ml FGF2 as
described (Barnabe´-Heider et al., 2005) from CD1 mice at a density
of 250,000 cells/ml. CNTF (Cedarlane Laboratories) was used at
50 ng/ml. AG490 (Calbiochem) and PD98059 (BIOMOL Research
Laboratories) were used at concentrations of 5 mM and 50 mM in
0.75% DMSO. ZVAD-FMK (Calbiochem) was used at a concentration
of 100 mM in 0.5% DMSO. Transfection conditions and plasmids are
described in the Supplemental Experimental Procedures. For clonal
analysis, precursors were cotransfected at very low densities with
EGFP and SHP-2 shRNA1 or D61G SHP-2 plasmids and were immu-
nostained at 4 or 6 DIV for EGFP, bIII-tubulin, and GFAP. In all exper-
iments, only clusters of isolated, EGFP-positive cells deriving from
single transfected precursors were analyzed.
In Utero Electroporation
In utero electroporation was performed as described (Barnabe´-Heider
et al., 2005; Paquin et al., 2005) with E13/E14 CD1 or Ta1:nlacZ
(Gloster et al., 1994) mice, injecting a nuclear EGFP expression plas-
mid driven from the EF1a promoter (pEF-EGFP) (as above) at a 1:3 ratio
with pSUPER-shRNA1, pEF-D61GSHP-2 or pEF-DPSHP-2, or pEF-
GM (empty vector), pSUPER scrambled as a control (5 mg/ml), and
0.05% trypan blue as a tracer. The square electroporator CUY21
EDIT (TR Tech, Japan) was used to deliver five 50 ms pulses of 50 V
with 950 ms intervals per embryo. Brains were dissected in ice-cold
HBSS, fixed in 4% PFA at 4C overnight, cryoprotected, and cryo-
sectioned coronally at 16 mm.
Immunocytochemistry and Quantification
Immunocytochemistry on cells was performed as described (Barnabe´-
Heider et al., 2005). For immunostaining of tissue, sections were post-
fixed with 4% PFA, blocked, and permeabilized with 10% BSA and
0.3% Triton X-100 and then with the M.O.M. blocking kit (Vector
Laboratories). Sections were incubated with primary antibodies at
4C overnight, with secondary antibodies at room temperature for
1 hr, counterstained with Hoechst 33258 (1:2000, Sigma-Aldrich),
Neuron
SHP-2 in Neural Precursor Cellsand mounted with GelTol (Fisher). Primary and secondary antibodies
are described in the Supplemental Experimental Procedures. For
quantification, over 200 transfected cells in at least eight randomly se-
lected fields spanning the wells of precursor cultures were counted
(per condition per experiment). In the clonal studies, 70–90 clones
were analyzed (per condition per experiment). For electroporated
brains, sections were analyzed with a Zeiss Pascal confocal micro-
scope and the manufacturer’s software. Three to four pictures per cor-
onal section were taken with a 403 objective, and a total of four sec-
tions per animal were analyzed and compared to equivalent sections in
littermate (or age-matched nonlittermate where indicated) counter-
parts. For quantitation of total cells, neurons, and astrocytes in SHP-
2 D61G/+ mice (Araki et al., 2004), mice were bred on a 129J/B6 back-
ground and brains harvested and processed as described above at
postnatal day 0 and 2. In blind analyses, three to four coronal tissue
sections were selected from the same rostral-caudal extent (based
upon hippocampal and cortical morphology) in brains of D61G/+ and
+/+ littermates and age-matched nonlittermates, and cell counts
were made from defined regions in the dorsal cortex and dentate
gyrus. Digital image acquisition and analysis was performed with
Northern Eclipse software (Empix Inc.) with a Sony XC-75CE CCD
video camera. Statistics were performed by using a Student’s t test,
unless indicated otherwise. ANOVA indicates a one-way ANOVA. Error
bars denote SEM in all cases.
Western Blot Analysis and Biochemistry
Cortical precursors and NIH 3T3 cells were lysed, 30–50 mg protein
lysate was run on SDS-PAGE, and western blots were performed as
described (Barnabe´-Heider et al., 2005).
Supplemental Data
The Supplemental Data for this article can be found online at http://
www.neuron.org/cgi/content/full/54/2/245/DC1/.
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